A collection of marijuana companies have been confirmed as some of the top-performing stocks on the Toronto Stock Exchange (TSX).

On Thursday (September 26), the senior Canadian exchange issued its first TSX30 list, presenting to investors the 30 highest-performing stocks over a three year time period. Five companies with exposure to the marijuana market were included.


Canopy Growth (NYSE:CGC,TSX:WEED) ended up at the top of the list, edging out Shopify (NYSE:SHOP,TSX:SHOP) for the leading position on the TSX30 list.

The rest of the cannabis players that made the TSX30 list are Village Farms International (NASDAQ:VFF,TSX:VFF) in the third spot, Aphria (NYSE:APHA,TSX:APHA) in the sixth spot and Neptune Wellness Solutions (NASDAQ:NEPT,TSX:NEPT) in the eighth spot.

Loui Anastasopoulos, president of capital formation and TSX trust with the TMX Group (TSX:X), said this new program recognizes “compelling success stories” in the Canadian markets, such as the “newly defined” cannabis space.

A representative for each company added to the TSX30 list will join members of the TMX executive team to open the market on Friday (September 27).

Canadian producers Canopy Growth and Aphria sell cannabis products in Canada and hold international expansion plans in the larger marijuana market. Neptune offers cannabis extraction services to producers of the drug. This process leads to the production of edibles and other novelty items.

While operating as an e-commerce technology company, Shopify offers a platform for the sale of marijuana products from established distributors.

Village Farms expects to see a bump to its financial results based on the progress of its half-owned cannabis producer joint venture, Pure Sunfarms. The venture is co-owned with Emerald Health Therapeutics (TSXV:EMH,OTCQX:EMHTF).

In a statement, Michael DeGiglio, founder and CEO of Village Farms, said that, while the award celebrates past performance, the company is working towards its path into the US the cannabis market.

“We expect to generate our first hemp biomass sales later this year, and then rapidly transition into higher margin (cannabidiol) CBD crude oil and then our own CBD products,” DeGiglio said of the company’s impending US market entry.

Don’t forget to follow us @INN_Cannabis for real-time news updates!

Securities Disclosure: I, Bryan Mc Govern, hold no direct investment interest in any company mentioned in this article.

Trading resumes in:

Company: Revive Therapeutics Ltd.

Keep reading... Show less

/NOT FOR DISTRIBUTION TO U.S. NEWSWIRE SERVICES OR DISSEMINATION IN THE UNITED STATES /

Revive Therapeutics Ltd. (” Revive ” or the ” Company “) (CSE:RVV) ( USA : RVVTF), a specialty life sciences company focused on the research and development of therapeutics for medical needs and rare disorders, is pleased to announce that it has entered into an amended agreement with Canaccord Genuity Corp. and Leede Jones Gable Inc. as the co-lead underwriters (collectively, the ” Underwriters “), to increase the size of its previously announced offering of units (the ” Equity Units “) at a price of $0.50 per Equity Unit. Under the amended terms, the Underwriters have agreed to purchase, on a bought deal basis, 40,000,000 Equity Units for gross proceeds to the Company of $20,000,000 (the ” Offering “). The over-allotment option granted to the Underwriters will proportionately increase to 15% of the Offering.

Keep reading... Show less

The new dispensary brings expanded access for patients in the growing communities of Central Florida

Trulieve Cannabis Corp. (CSE: TRUL) (OTCQX: TCNNF) (“Trulieve” or “the Company”), a leading and top-performing cannabis company based in the United States announced today the opening of a brand-new Florida dispensary, the Company’s 77th nationwide. The new, 5,100 sq. ft. location marks the Company’s first in Summerfield expanding patient access to Florida’s largest and broadest assortment of high-quality medical cannabis products.

Keep reading... Show less

BioHarvest Sciences Inc. (CSE: BHSC) (“BioHarvest” or the “Company”).

The Company announced today that its board of directors have approved a private placement of up to 15,000,000 units at a price of $.40 per unit for gross proceeds of up to $6,000,000. Each unit will consist of one common share of the Company and one share purchase warrant. Each share purchase warrant will be exercisable to purchase an additional common share at a fixed price of $.45 per share for a period of one year from closing.

Keep reading... Show less

The following issues have been halted by IIROC:

Company: Revive Therapeutics Ltd.

Keep reading... Show less